CG Oncology appoints Christina Rossi to board of directors

IRVINE, Calif. - CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on bladder cancer therapeutics, announced Wednesday the appointment of Christina Rossi to its Board of Directors. The company’s stock is currently trading at $45.51, near its 52-week high of $45.56, with an impressive 78.9% price return over the past six months, according to InvestingPro data.

The company also reported that Simone Song, Senior Partner at ORI Capital, has resigned from the Board effective November 22, 2025, after more than a decade of service.

Rossi brings over 25 years of pharmaceutical and biotechnology experience to CG Oncology. She most recently served as Chief Operating Officer of Blueprint Medicines until its acquisition by Sanofi in 2025. Prior to that role, she was Chief Commercial Officer at Blueprint, where she oversaw multiple therapy launches and established commercial infrastructure in the U.S. and Europe.

Her previous experience includes leadership positions at Sanofi Genzyme, where she served as Multiple Sclerosis Business Unit Head for North America, and various roles at Biogen Inc. Rossi holds a B.S. in biology from Duke University and an M.B.A. from Harvard Business School.

The appointment comes as CG Oncology has initiated a Biologics License Application (BLA) for cretostimogene, its investigational bladder cancer therapy. The company’s lead candidate has been studied in over 400 patients with Non-Muscle Invasive Bladder Cancer across multiple clinical trials.

Arthur Kuan, Chairman and Chief Executive Officer of CG Oncology, stated in the press release that the company is "laying the foundation for a successful launch upon FDA approval" of cretostimogene.

The therapy remains investigational and has not yet received approval from the FDA or other health authorities.

In other recent news, CG Oncology has been the subject of several analyst actions and announcements related to its ongoing Biologics License Application (BLA) for its lead product, Creto. The company reported its third-quarter 2025 earnings, coinciding with the initiation of its BLA filing, which has been a focal point for investors. RBC Capital responded by raising its price target for CG Oncology from $53.00 to $61.00, maintaining an Outperform rating. Meanwhile, Truist Securities initiated coverage with a Buy rating and a $62.00 price target, noting the potential approval of Creto in late 2026. Guggenheim also started coverage with a Buy rating, setting a higher price target of $90.00 due to Creto’s anticipated impact in the non-muscle invasive bladder cancer market. H.C. Wainwright reiterated its Buy rating and $75.00 price target, addressing investor inquiries about the pricing of a competing therapy, Inlexzo. Additionally, Jones Trading initiated coverage with a Buy rating and a $50.00 price target, focusing on Creto’s development for various treatment settings. These developments highlight the growing interest and expectations from analysts regarding CG Oncology’s future prospects.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.